Urological Cancer Drugs-Global Market Status & Trend Report 2013-2023 Top 20 Countries Data
Report Summary
Urological Cancer Drugs-Global Market Status & Trend Report 2013-2023 Top 20 Countries Data offers a comprehensive analysis on Urological Cancer Drugs industry, standing on the readers? perspective, delivering detailed market data in Global major 20 countries and penetrating insights. No matter the client is industry insider, potential entrant or investor, the report will provides useful data and information. Key questions answered by this report include:
Worldwide and Top 20 Countries Market Size of Urological Cancer Drugs 2013-2017, and development forecast 2018-2023
Main manufacturers/suppliers of Urological Cancer Drugs worldwide and market share by regions, with company and product introduction, position in the Urological Cancer Drugs market
Market status and development trend of Urological Cancer Drugs by types and applications
Cost and profit status of Urological Cancer Drugs, and marketing status
Market growth drivers and challenges
The report segments the global Urological Cancer Drugs market as:
Global Urological Cancer Drugs Market: Regional Segment Analysis (Regional Production Volume, Consumption Volume, Revenue and Growth Rate 2013-2023):
North America (United States, Canada and Mexico)
Europe (Germany, UK, France, Italy, Russia, Spain and Benelux)
Asia Pacific (China, Japan, India, Southeast Asia and Australia)
Latin America (Brazil, Argentina and Colombia)
Middle East and Africa
Global Urological Cancer Drugs Market: Type Segment Analysis (Consumption Volume, Average Price, Revenue, Market Share and Trend 2013-2023):
Xofigo (Radium Ra 223 Dichloride)
Jevtana (Cabazitaxel)
Inlyta (Axitinib)
Votrient (Pazopanib Hydrochloride)
Sutent (Sunitinib Malate)
Zytiga (Abiraterone Acetate)
Xtandi (Enzalutamide)
Opdivo (Nivolumab)
Provenge (Sipuleucel-T)
Global Urological Cancer Drugs Market: Application Segment Analysis (Consumption Volume and Market Share 2013-2023; Downstream Customers and Market Analysis)
Prostate Cancer
Bladder Cancer
Kidney Cancer
Testicular Cancer
Global Urological Cancer Drugs Market: Manufacturers Segment Analysis (Company and Product introduction, Urological Cancer Drugs Sales Volume, Revenue, Price and Gross Margin):
Novartis
Pfizer
Johnson & Johnson
AstraZeneca
Astellas
Bristol-Myers Squibb
Abbott Laboratories
Celgene Corporation
Dendreon Corporation
Ferring Pharmaceuticals
GlaxoSmithKline
Indevus Pharmaceuticals Inc
Ipsen
Roche Healthcare
Sanofi S.A.
Tolmar Inc
In a word, the report provides detailed statistics and analysis on the state of the industry; and is a valuable source of guidance and direction for companies and individuals interested in the market.
Urological Cancer Drugs-Global Market Status & Trend Report 2013-2023 Top 20 Countries Data offers a comprehensive analysis on Urological Cancer Drugs industry, standing on the readers? perspective, delivering detailed market data in Global major 20 countries and penetrating insights. No matter the client is industry insider, potential entrant or investor, the report will provides useful data and information. Key questions answered by this report include:
Worldwide and Top 20 Countries Market Size of Urological Cancer Drugs 2013-2017, and development forecast 2018-2023
Main manufacturers/suppliers of Urological Cancer Drugs worldwide and market share by regions, with company and product introduction, position in the Urological Cancer Drugs market
Market status and development trend of Urological Cancer Drugs by types and applications
Cost and profit status of Urological Cancer Drugs, and marketing status
Market growth drivers and challenges
The report segments the global Urological Cancer Drugs market as:
Global Urological Cancer Drugs Market: Regional Segment Analysis (Regional Production Volume, Consumption Volume, Revenue and Growth Rate 2013-2023):
North America (United States, Canada and Mexico)
Europe (Germany, UK, France, Italy, Russia, Spain and Benelux)
Asia Pacific (China, Japan, India, Southeast Asia and Australia)
Latin America (Brazil, Argentina and Colombia)
Middle East and Africa
Global Urological Cancer Drugs Market: Type Segment Analysis (Consumption Volume, Average Price, Revenue, Market Share and Trend 2013-2023):
Xofigo (Radium Ra 223 Dichloride)
Jevtana (Cabazitaxel)
Inlyta (Axitinib)
Votrient (Pazopanib Hydrochloride)
Sutent (Sunitinib Malate)
Zytiga (Abiraterone Acetate)
Xtandi (Enzalutamide)
Opdivo (Nivolumab)
Provenge (Sipuleucel-T)
Global Urological Cancer Drugs Market: Application Segment Analysis (Consumption Volume and Market Share 2013-2023; Downstream Customers and Market Analysis)
Prostate Cancer
Bladder Cancer
Kidney Cancer
Testicular Cancer
Global Urological Cancer Drugs Market: Manufacturers Segment Analysis (Company and Product introduction, Urological Cancer Drugs Sales Volume, Revenue, Price and Gross Margin):
Novartis
Pfizer
Johnson & Johnson
AstraZeneca
Astellas
Bristol-Myers Squibb
Abbott Laboratories
Celgene Corporation
Dendreon Corporation
Ferring Pharmaceuticals
GlaxoSmithKline
Indevus Pharmaceuticals Inc
Ipsen
Roche Healthcare
Sanofi S.A.
Tolmar Inc
In a word, the report provides detailed statistics and analysis on the state of the industry; and is a valuable source of guidance and direction for companies and individuals interested in the market.
CHAPTER 1 OVERVIEW OF UROLOGICAL CANCER DRUGS
1.1 Definition of Urological Cancer Drugs in This Report
1.2 Commercial Types of Urological Cancer Drugs
1.2.1 Xofigo (Radium Ra 223 Dichloride)
1.2.2 Jevtana (Cabazitaxel)
1.2.3 Inlyta (Axitinib)
1.2.4 Votrient (Pazopanib Hydrochloride)
1.2.5 Sutent (Sunitinib Malate)
1.2.6 Zytiga (Abiraterone Acetate)
1.2.7 Xtandi (Enzalutamide)
1.2.8 Opdivo (Nivolumab)
1.2.9 Provenge (Sipuleucel-T)
1.3 Downstream Application of Urological Cancer Drugs
1.3.1 Prostate Cancer
1.3.2 Bladder Cancer
1.3.3 Kidney Cancer
1.3.4 Testicular Cancer
1.4 Development History of Urological Cancer Drugs
1.5 Market Status and Trend of Urological Cancer Drugs 2013-2023
1.5.1 Global Urological Cancer Drugs Market Status and Trend 2013-2023
1.5.2 Regional Urological Cancer Drugs Market Status and Trend 2013-2023
CHAPTER 2 GLOBAL MARKET STATUS AND FORECAST BY REGIONS
2.1 Market Development of Urological Cancer Drugs 2013-2017
2.2 Sales Market of Urological Cancer Drugs by Regions
2.2.1 Sales Volume of Urological Cancer Drugs by Regions
2.2.2 Sales Value of Urological Cancer Drugs by Regions
2.3 Production Market of Urological Cancer Drugs by Regions
2.4 Global Market Forecast of Urological Cancer Drugs 2018-2023
2.4.1 Global Market Forecast of Urological Cancer Drugs 2018-2023
2.4.2 Market Forecast of Urological Cancer Drugs by Regions 2018-2023
CHAPTER 3 GLOBAL MARKET STATUS AND FORECAST BY TYPES
3.1 Sales Volume of Urological Cancer Drugs by Types
3.2 Sales Value of Urological Cancer Drugs by Types
3.3 Market Forecast of Urological Cancer Drugs by Types
CHAPTER 4 GLOBAL MARKET STATUS AND FORECAST BY DOWNSTREAM INDUSTRY
4.1 Global Sales Volume of Urological Cancer Drugs by Downstream Industry
4.2 Global Market Forecast of Urological Cancer Drugs by Downstream Industry
CHAPTER 5 NORTH AMERICA MARKET STATUS BY COUNTRIES, TYPE, MANUFACTURERS AND DOWNSTREAM INDUSTRY
5.1 North America Urological Cancer Drugs Market Status by Countries
5.1.1 North America Urological Cancer Drugs Sales by Countries (2013-2017)
5.1.2 North America Urological Cancer Drugs Revenue by Countries (2013-2017)
5.1.3 United States Urological Cancer Drugs Market Status (2013-2017)
5.1.4 Canada Urological Cancer Drugs Market Status (2013-2017)
5.1.5 Mexico Urological Cancer Drugs Market Status (2013-2017)
5.2 North America Urological Cancer Drugs Market Status by Manufacturers
5.3 North America Urological Cancer Drugs Market Status by Type (2013-2017)
5.3.1 North America Urological Cancer Drugs Sales by Type (2013-2017)
5.3.2 North America Urological Cancer Drugs Revenue by Type (2013-2017)
5.4 North America Urological Cancer Drugs Market Status by Downstream Industry (2013-2017)
CHAPTER 6 EUROPE MARKET STATUS BY COUNTRIES, TYPE, MANUFACTURERS AND DOWNSTREAM INDUSTRY
6.1 Europe Urological Cancer Drugs Market Status by Countries
6.1.1 Europe Urological Cancer Drugs Sales by Countries (2013-2017)
6.1.2 Europe Urological Cancer Drugs Revenue by Countries (2013-2017)
6.1.3 Germany Urological Cancer Drugs Market Status (2013-2017)
6.1.4 UK Urological Cancer Drugs Market Status (2013-2017)
6.1.5 France Urological Cancer Drugs Market Status (2013-2017)
6.1.6 Italy Urological Cancer Drugs Market Status (2013-2017)
6.1.7 Russia Urological Cancer Drugs Market Status (2013-2017)
6.1.8 Spain Urological Cancer Drugs Market Status (2013-2017)
6.1.9 Benelux Urological Cancer Drugs Market Status (2013-2017)
6.2 Europe Urological Cancer Drugs Market Status by Manufacturers
6.3 Europe Urological Cancer Drugs Market Status by Type (2013-2017)
6.3.1 Europe Urological Cancer Drugs Sales by Type (2013-2017)
6.3.2 Europe Urological Cancer Drugs Revenue by Type (2013-2017)
6.4 Europe Urological Cancer Drugs Market Status by Downstream Industry (2013-2017)
CHAPTER 7 ASIA PACIFIC MARKET STATUS BY COUNTRIES, TYPE, MANUFACTURERS AND DOWNSTREAM INDUSTRY
7.1 Asia Pacific Urological Cancer Drugs Market Status by Countries
7.1.1 Asia Pacific Urological Cancer Drugs Sales by Countries (2013-2017)
7.1.2 Asia Pacific Urological Cancer Drugs Revenue by Countries (2013-2017)
7.1.3 China Urological Cancer Drugs Market Status (2013-2017)
7.1.4 Japan Urological Cancer Drugs Market Status (2013-2017)
7.1.5 India Urological Cancer Drugs Market Status (2013-2017)
7.1.6 Southeast Asia Urological Cancer Drugs Market Status (2013-2017)
7.1.7 Australia Urological Cancer Drugs Market Status (2013-2017)
7.2 Asia Pacific Urological Cancer Drugs Market Status by Manufacturers
7.3 Asia Pacific Urological Cancer Drugs Market Status by Type (2013-2017)
7.3.1 Asia Pacific Urological Cancer Drugs Sales by Type (2013-2017)
7.3.2 Asia Pacific Urological Cancer Drugs Revenue by Type (2013-2017)
7.4 Asia Pacific Urological Cancer Drugs Market Status by Downstream Industry (2013-2017)
CHAPTER 8 LATIN AMERICA MARKET STATUS BY COUNTRIES, TYPE, MANUFACTURERS AND DOWNSTREAM INDUSTRY
8.1 Latin America Urological Cancer Drugs Market Status by Countries
8.1.1 Latin America Urological Cancer Drugs Sales by Countries (2013-2017)
8.1.2 Latin America Urological Cancer Drugs Revenue by Countries (2013-2017)
8.1.3 Brazil Urological Cancer Drugs Market Status (2013-2017)
8.1.4 Argentina Urological Cancer Drugs Market Status (2013-2017)
8.1.5 Colombia Urological Cancer Drugs Market Status (2013-2017)
8.2 Latin America Urological Cancer Drugs Market Status by Manufacturers
8.3 Latin America Urological Cancer Drugs Market Status by Type (2013-2017)
8.3.1 Latin America Urological Cancer Drugs Sales by Type (2013-2017)
8.3.2 Latin America Urological Cancer Drugs Revenue by Type (2013-2017)
8.4 Latin America Urological Cancer Drugs Market Status by Downstream Industry (2013-2017)
CHAPTER 9 MIDDLE EAST AND AFRICA MARKET STATUS BY COUNTRIES, TYPE, MANUFACTURERS AND DOWNSTREAM INDUSTRY
9.1 Middle East and Africa Urological Cancer Drugs Market Status by Countries
9.1.1 Middle East and Africa Urological Cancer Drugs Sales by Countries (2013-2017)
9.1.2 Middle East and Africa Urological Cancer Drugs Revenue by Countries (2013-2017)
9.1.3 Middle East Urological Cancer Drugs Market Status (2013-2017)
9.1.4 Africa Urological Cancer Drugs Market Status (2013-2017)
9.2 Middle East and Africa Urological Cancer Drugs Market Status by Manufacturers
9.3 Middle East and Africa Urological Cancer Drugs Market Status by Type (2013-2017)
9.3.1 Middle East and Africa Urological Cancer Drugs Sales by Type (2013-2017)
9.3.2 Middle East and Africa Urological Cancer Drugs Revenue by Type (2013-2017)
9.4 Middle East and Africa Urological Cancer Drugs Market Status by Downstream Industry (2013-2017)
CHAPTER 10 MARKET DRIVING FACTOR ANALYSIS OF UROLOGICAL CANCER DRUGS
10.1 Global Economy Situation and Trend Overview
10.2 Urological Cancer Drugs Downstream Industry Situation and Trend Overview
CHAPTER 11 UROLOGICAL CANCER DRUGS MARKET COMPETITION STATUS BY MAJOR MANUFACTURERS
11.1 Production Volume of Urological Cancer Drugs by Major Manufacturers
11.2 Production Value of Urological Cancer Drugs by Major Manufacturers
11.3 Basic Information of Urological Cancer Drugs by Major Manufacturers
11.3.1 Headquarters Location and Established Time of Urological Cancer Drugs Major Manufacturer
11.3.2 Employees and Revenue Level of Urological Cancer Drugs Major Manufacturer
11.4 Market Competition News and Trend
11.4.1 Merger, Consolidation or Acquisition News
11.4.2 Investment or Disinvestment News
11.4.3 New Product Development and Launch
CHAPTER 12 UROLOGICAL CANCER DRUGS MAJOR MANUFACTURERS INTRODUCTION AND MARKET DATA
12.1 Novartis
12.1.1 Company profile
12.1.2 Representative Urological Cancer Drugs Product
12.1.3 Urological Cancer Drugs Sales, Revenue, Price and Gross Margin of Novartis
12.2 Pfizer
12.2.1 Company profile
12.2.2 Representative Urological Cancer Drugs Product
12.2.3 Urological Cancer Drugs Sales, Revenue, Price and Gross Margin of Pfizer
12.3 Johnson & Johnson
12.3.1 Company profile
12.3.2 Representative Urological Cancer Drugs Product
12.3.3 Urological Cancer Drugs Sales, Revenue, Price and Gross Margin of Johnson & Johnson
12.4 AstraZeneca
12.4.1 Company profile
12.4.2 Representative Urological Cancer Drugs Product
12.4.3 Urological Cancer Drugs Sales, Revenue, Price and Gross Margin of AstraZeneca
12.5 Astellas
12.5.1 Company profile
12.5.2 Representative Urological Cancer Drugs Product
12.5.3 Urological Cancer Drugs Sales, Revenue, Price and Gross Margin of Astellas
12.6 Bristol-Myers Squibb
12.6.1 Company profile
12.6.2 Representative Urological Cancer Drugs Product
12.6.3 Urological Cancer Drugs Sales, Revenue, Price and Gross Margin of Bristol-Myers Squibb
12.7 Abbott Laboratories
12.7.1 Company profile
12.7.2 Representative Urological Cancer Drugs Product
12.7.3 Urological Cancer Drugs Sales, Revenue, Price and Gross Margin of Abbott Laboratories
12.8 Celgene Corporation
12.8.1 Company profile
12.8.2 Representative Urological Cancer Drugs Product
12.8.3 Urological Cancer Drugs Sales, Revenue, Price and Gross Margin of Celgene Corporation
12.9 Dendreon Corporation
12.9.1 Company profile
12.9.2 Representative Urological Cancer Drugs Product
12.9.3 Urological Cancer Drugs Sales, Revenue, Price and Gross Margin of Dendreon Corporation
12.10 Ferring Pharmaceuticals
12.10.1 Company profile
12.10.2 Representative Urological Cancer Drugs Product
12.10.3 Urological Cancer Drugs Sales, Revenue, Price and Gross Margin of Ferring Pharmaceuticals
12.11 GlaxoSmithKline
12.11.1 Company profile
12.11.2 Representative Urological Cancer Drugs Product
12.11.3 Urological Cancer Drugs Sales, Revenue, Price and Gross Margin of GlaxoSmithKline
12.12 Indevus Pharmaceuticals Inc
12.12.1 Company profile
12.12.2 Representative Urological Cancer Drugs Product
12.12.3 Urological Cancer Drugs Sales, Revenue, Price and Gross Margin of Indevus Pharmaceuticals Inc
12.13 Ipsen
12.13.1 Company profile
12.13.2 Representative Urological Cancer Drugs Product
12.13.3 Urological Cancer Drugs Sales, Revenue, Price and Gross Margin of Ipsen
12.14 Roche Healthcare
12.14.1 Company profile
12.14.2 Representative Urological Cancer Drugs Product
12.14.3 Urological Cancer Drugs Sales, Revenue, Price and Gross Margin of Roche Healthcare
12.15 Sanofi S.A.
12.15.1 Company profile
12.15.2 Representative Urological Cancer Drugs Product
12.15.3 Urological Cancer Drugs Sales, Revenue, Price and Gross Margin of Sanofi S.A.
12.16 Tolmar Inc
CHAPTER 13 UPSTREAM AND DOWNSTREAM MARKET ANALYSIS OF UROLOGICAL CANCER DRUGS
13.1 Industry Chain of Urological Cancer Drugs
13.2 Upstream Market and Representative Companies Analysis
13.3 Downstream Market and Representative Companies Analysis
CHAPTER 14 COST AND GROSS MARGIN ANALYSIS OF UROLOGICAL CANCER DRUGS
14.1 Cost Structure Analysis of Urological Cancer Drugs
14.2 Raw Materials Cost Analysis of Urological Cancer Drugs
14.3 Labor Cost Analysis of Urological Cancer Drugs
14.4 Manufacturing Expenses Analysis of Urological Cancer Drugs
CHAPTER 15 REPORT CONCLUSION
CHAPTER 16 RESEARCH METHODOLOGY AND REFERENCE
16.1 Methodology/Research Approach
16.1.1 Research Programs/Design
16.1.2 Market Size Estimation
16.1.3 Market Breakdown and Data Triangulation
16.2 Data Source
16.2.1 Secondary Sources
16.2.2 Primary Sources
16.3 Reference
1.1 Definition of Urological Cancer Drugs in This Report
1.2 Commercial Types of Urological Cancer Drugs
1.2.1 Xofigo (Radium Ra 223 Dichloride)
1.2.2 Jevtana (Cabazitaxel)
1.2.3 Inlyta (Axitinib)
1.2.4 Votrient (Pazopanib Hydrochloride)
1.2.5 Sutent (Sunitinib Malate)
1.2.6 Zytiga (Abiraterone Acetate)
1.2.7 Xtandi (Enzalutamide)
1.2.8 Opdivo (Nivolumab)
1.2.9 Provenge (Sipuleucel-T)
1.3 Downstream Application of Urological Cancer Drugs
1.3.1 Prostate Cancer
1.3.2 Bladder Cancer
1.3.3 Kidney Cancer
1.3.4 Testicular Cancer
1.4 Development History of Urological Cancer Drugs
1.5 Market Status and Trend of Urological Cancer Drugs 2013-2023
1.5.1 Global Urological Cancer Drugs Market Status and Trend 2013-2023
1.5.2 Regional Urological Cancer Drugs Market Status and Trend 2013-2023
CHAPTER 2 GLOBAL MARKET STATUS AND FORECAST BY REGIONS
2.1 Market Development of Urological Cancer Drugs 2013-2017
2.2 Sales Market of Urological Cancer Drugs by Regions
2.2.1 Sales Volume of Urological Cancer Drugs by Regions
2.2.2 Sales Value of Urological Cancer Drugs by Regions
2.3 Production Market of Urological Cancer Drugs by Regions
2.4 Global Market Forecast of Urological Cancer Drugs 2018-2023
2.4.1 Global Market Forecast of Urological Cancer Drugs 2018-2023
2.4.2 Market Forecast of Urological Cancer Drugs by Regions 2018-2023
CHAPTER 3 GLOBAL MARKET STATUS AND FORECAST BY TYPES
3.1 Sales Volume of Urological Cancer Drugs by Types
3.2 Sales Value of Urological Cancer Drugs by Types
3.3 Market Forecast of Urological Cancer Drugs by Types
CHAPTER 4 GLOBAL MARKET STATUS AND FORECAST BY DOWNSTREAM INDUSTRY
4.1 Global Sales Volume of Urological Cancer Drugs by Downstream Industry
4.2 Global Market Forecast of Urological Cancer Drugs by Downstream Industry
CHAPTER 5 NORTH AMERICA MARKET STATUS BY COUNTRIES, TYPE, MANUFACTURERS AND DOWNSTREAM INDUSTRY
5.1 North America Urological Cancer Drugs Market Status by Countries
5.1.1 North America Urological Cancer Drugs Sales by Countries (2013-2017)
5.1.2 North America Urological Cancer Drugs Revenue by Countries (2013-2017)
5.1.3 United States Urological Cancer Drugs Market Status (2013-2017)
5.1.4 Canada Urological Cancer Drugs Market Status (2013-2017)
5.1.5 Mexico Urological Cancer Drugs Market Status (2013-2017)
5.2 North America Urological Cancer Drugs Market Status by Manufacturers
5.3 North America Urological Cancer Drugs Market Status by Type (2013-2017)
5.3.1 North America Urological Cancer Drugs Sales by Type (2013-2017)
5.3.2 North America Urological Cancer Drugs Revenue by Type (2013-2017)
5.4 North America Urological Cancer Drugs Market Status by Downstream Industry (2013-2017)
CHAPTER 6 EUROPE MARKET STATUS BY COUNTRIES, TYPE, MANUFACTURERS AND DOWNSTREAM INDUSTRY
6.1 Europe Urological Cancer Drugs Market Status by Countries
6.1.1 Europe Urological Cancer Drugs Sales by Countries (2013-2017)
6.1.2 Europe Urological Cancer Drugs Revenue by Countries (2013-2017)
6.1.3 Germany Urological Cancer Drugs Market Status (2013-2017)
6.1.4 UK Urological Cancer Drugs Market Status (2013-2017)
6.1.5 France Urological Cancer Drugs Market Status (2013-2017)
6.1.6 Italy Urological Cancer Drugs Market Status (2013-2017)
6.1.7 Russia Urological Cancer Drugs Market Status (2013-2017)
6.1.8 Spain Urological Cancer Drugs Market Status (2013-2017)
6.1.9 Benelux Urological Cancer Drugs Market Status (2013-2017)
6.2 Europe Urological Cancer Drugs Market Status by Manufacturers
6.3 Europe Urological Cancer Drugs Market Status by Type (2013-2017)
6.3.1 Europe Urological Cancer Drugs Sales by Type (2013-2017)
6.3.2 Europe Urological Cancer Drugs Revenue by Type (2013-2017)
6.4 Europe Urological Cancer Drugs Market Status by Downstream Industry (2013-2017)
CHAPTER 7 ASIA PACIFIC MARKET STATUS BY COUNTRIES, TYPE, MANUFACTURERS AND DOWNSTREAM INDUSTRY
7.1 Asia Pacific Urological Cancer Drugs Market Status by Countries
7.1.1 Asia Pacific Urological Cancer Drugs Sales by Countries (2013-2017)
7.1.2 Asia Pacific Urological Cancer Drugs Revenue by Countries (2013-2017)
7.1.3 China Urological Cancer Drugs Market Status (2013-2017)
7.1.4 Japan Urological Cancer Drugs Market Status (2013-2017)
7.1.5 India Urological Cancer Drugs Market Status (2013-2017)
7.1.6 Southeast Asia Urological Cancer Drugs Market Status (2013-2017)
7.1.7 Australia Urological Cancer Drugs Market Status (2013-2017)
7.2 Asia Pacific Urological Cancer Drugs Market Status by Manufacturers
7.3 Asia Pacific Urological Cancer Drugs Market Status by Type (2013-2017)
7.3.1 Asia Pacific Urological Cancer Drugs Sales by Type (2013-2017)
7.3.2 Asia Pacific Urological Cancer Drugs Revenue by Type (2013-2017)
7.4 Asia Pacific Urological Cancer Drugs Market Status by Downstream Industry (2013-2017)
CHAPTER 8 LATIN AMERICA MARKET STATUS BY COUNTRIES, TYPE, MANUFACTURERS AND DOWNSTREAM INDUSTRY
8.1 Latin America Urological Cancer Drugs Market Status by Countries
8.1.1 Latin America Urological Cancer Drugs Sales by Countries (2013-2017)
8.1.2 Latin America Urological Cancer Drugs Revenue by Countries (2013-2017)
8.1.3 Brazil Urological Cancer Drugs Market Status (2013-2017)
8.1.4 Argentina Urological Cancer Drugs Market Status (2013-2017)
8.1.5 Colombia Urological Cancer Drugs Market Status (2013-2017)
8.2 Latin America Urological Cancer Drugs Market Status by Manufacturers
8.3 Latin America Urological Cancer Drugs Market Status by Type (2013-2017)
8.3.1 Latin America Urological Cancer Drugs Sales by Type (2013-2017)
8.3.2 Latin America Urological Cancer Drugs Revenue by Type (2013-2017)
8.4 Latin America Urological Cancer Drugs Market Status by Downstream Industry (2013-2017)
CHAPTER 9 MIDDLE EAST AND AFRICA MARKET STATUS BY COUNTRIES, TYPE, MANUFACTURERS AND DOWNSTREAM INDUSTRY
9.1 Middle East and Africa Urological Cancer Drugs Market Status by Countries
9.1.1 Middle East and Africa Urological Cancer Drugs Sales by Countries (2013-2017)
9.1.2 Middle East and Africa Urological Cancer Drugs Revenue by Countries (2013-2017)
9.1.3 Middle East Urological Cancer Drugs Market Status (2013-2017)
9.1.4 Africa Urological Cancer Drugs Market Status (2013-2017)
9.2 Middle East and Africa Urological Cancer Drugs Market Status by Manufacturers
9.3 Middle East and Africa Urological Cancer Drugs Market Status by Type (2013-2017)
9.3.1 Middle East and Africa Urological Cancer Drugs Sales by Type (2013-2017)
9.3.2 Middle East and Africa Urological Cancer Drugs Revenue by Type (2013-2017)
9.4 Middle East and Africa Urological Cancer Drugs Market Status by Downstream Industry (2013-2017)
CHAPTER 10 MARKET DRIVING FACTOR ANALYSIS OF UROLOGICAL CANCER DRUGS
10.1 Global Economy Situation and Trend Overview
10.2 Urological Cancer Drugs Downstream Industry Situation and Trend Overview
CHAPTER 11 UROLOGICAL CANCER DRUGS MARKET COMPETITION STATUS BY MAJOR MANUFACTURERS
11.1 Production Volume of Urological Cancer Drugs by Major Manufacturers
11.2 Production Value of Urological Cancer Drugs by Major Manufacturers
11.3 Basic Information of Urological Cancer Drugs by Major Manufacturers
11.3.1 Headquarters Location and Established Time of Urological Cancer Drugs Major Manufacturer
11.3.2 Employees and Revenue Level of Urological Cancer Drugs Major Manufacturer
11.4 Market Competition News and Trend
11.4.1 Merger, Consolidation or Acquisition News
11.4.2 Investment or Disinvestment News
11.4.3 New Product Development and Launch
CHAPTER 12 UROLOGICAL CANCER DRUGS MAJOR MANUFACTURERS INTRODUCTION AND MARKET DATA
12.1 Novartis
12.1.1 Company profile
12.1.2 Representative Urological Cancer Drugs Product
12.1.3 Urological Cancer Drugs Sales, Revenue, Price and Gross Margin of Novartis
12.2 Pfizer
12.2.1 Company profile
12.2.2 Representative Urological Cancer Drugs Product
12.2.3 Urological Cancer Drugs Sales, Revenue, Price and Gross Margin of Pfizer
12.3 Johnson & Johnson
12.3.1 Company profile
12.3.2 Representative Urological Cancer Drugs Product
12.3.3 Urological Cancer Drugs Sales, Revenue, Price and Gross Margin of Johnson & Johnson
12.4 AstraZeneca
12.4.1 Company profile
12.4.2 Representative Urological Cancer Drugs Product
12.4.3 Urological Cancer Drugs Sales, Revenue, Price and Gross Margin of AstraZeneca
12.5 Astellas
12.5.1 Company profile
12.5.2 Representative Urological Cancer Drugs Product
12.5.3 Urological Cancer Drugs Sales, Revenue, Price and Gross Margin of Astellas
12.6 Bristol-Myers Squibb
12.6.1 Company profile
12.6.2 Representative Urological Cancer Drugs Product
12.6.3 Urological Cancer Drugs Sales, Revenue, Price and Gross Margin of Bristol-Myers Squibb
12.7 Abbott Laboratories
12.7.1 Company profile
12.7.2 Representative Urological Cancer Drugs Product
12.7.3 Urological Cancer Drugs Sales, Revenue, Price and Gross Margin of Abbott Laboratories
12.8 Celgene Corporation
12.8.1 Company profile
12.8.2 Representative Urological Cancer Drugs Product
12.8.3 Urological Cancer Drugs Sales, Revenue, Price and Gross Margin of Celgene Corporation
12.9 Dendreon Corporation
12.9.1 Company profile
12.9.2 Representative Urological Cancer Drugs Product
12.9.3 Urological Cancer Drugs Sales, Revenue, Price and Gross Margin of Dendreon Corporation
12.10 Ferring Pharmaceuticals
12.10.1 Company profile
12.10.2 Representative Urological Cancer Drugs Product
12.10.3 Urological Cancer Drugs Sales, Revenue, Price and Gross Margin of Ferring Pharmaceuticals
12.11 GlaxoSmithKline
12.11.1 Company profile
12.11.2 Representative Urological Cancer Drugs Product
12.11.3 Urological Cancer Drugs Sales, Revenue, Price and Gross Margin of GlaxoSmithKline
12.12 Indevus Pharmaceuticals Inc
12.12.1 Company profile
12.12.2 Representative Urological Cancer Drugs Product
12.12.3 Urological Cancer Drugs Sales, Revenue, Price and Gross Margin of Indevus Pharmaceuticals Inc
12.13 Ipsen
12.13.1 Company profile
12.13.2 Representative Urological Cancer Drugs Product
12.13.3 Urological Cancer Drugs Sales, Revenue, Price and Gross Margin of Ipsen
12.14 Roche Healthcare
12.14.1 Company profile
12.14.2 Representative Urological Cancer Drugs Product
12.14.3 Urological Cancer Drugs Sales, Revenue, Price and Gross Margin of Roche Healthcare
12.15 Sanofi S.A.
12.15.1 Company profile
12.15.2 Representative Urological Cancer Drugs Product
12.15.3 Urological Cancer Drugs Sales, Revenue, Price and Gross Margin of Sanofi S.A.
12.16 Tolmar Inc
CHAPTER 13 UPSTREAM AND DOWNSTREAM MARKET ANALYSIS OF UROLOGICAL CANCER DRUGS
13.1 Industry Chain of Urological Cancer Drugs
13.2 Upstream Market and Representative Companies Analysis
13.3 Downstream Market and Representative Companies Analysis
CHAPTER 14 COST AND GROSS MARGIN ANALYSIS OF UROLOGICAL CANCER DRUGS
14.1 Cost Structure Analysis of Urological Cancer Drugs
14.2 Raw Materials Cost Analysis of Urological Cancer Drugs
14.3 Labor Cost Analysis of Urological Cancer Drugs
14.4 Manufacturing Expenses Analysis of Urological Cancer Drugs
CHAPTER 15 REPORT CONCLUSION
CHAPTER 16 RESEARCH METHODOLOGY AND REFERENCE
16.1 Methodology/Research Approach
16.1.1 Research Programs/Design
16.1.2 Market Size Estimation
16.1.3 Market Breakdown and Data Triangulation
16.2 Data Source
16.2.1 Secondary Sources
16.2.2 Primary Sources
16.3 Reference
